Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

Inclusion Criteria: 1. Patients who the disease evaluation score is more than 14 at study medication received. 2. Patients with corticosteroids over 20mg/day(Prednisolone) at study medication received and continued this treatment more than 2 days. 3. Patients with treatment effect is insufficiency before study medication received and need additional treatment. 4. Patients aged more than twenty years old at informed consent. Exclusion Criteria: 1. Patients who the SCORTEN score is more than 4 at study medication received. 2. Patients with multiple organ failure at study medication received. 3. Patients with severe respiratory disorder at study medication received. 4. Patients with Drug-induced hypersensitivity syndrome (DIHS) at informed consent. 5. Patients with malignancy during treatment at informed consent. 6. Patients treated with corticosteroids dosage is change at 2 days before study medication received. 7. Patients treated with corticosteroids pulse therapy(including semi-pulse therapy) at 2 days before study medication received. 8. Patients treated with plasmapheresis at 2 days before study medication received. 9. Patients treated with high-dose intravenous immunoglobulin at 28 days before informed consent. 10. Patients with history of shock or hypersensitivity for NPB-01. 11. Patients with IgA deficiency. 12. Patients with severe impaired liver function diagnosed virus hepatitis or cirrhosis et al. 13. Patients with more than 2mg/dL serum creatinine. 14. Patients with severe cerebro- or cardiovascular disorders. 15. Patients with high risk of thromboembolism. 16. Patients with hemolytic/hemorrhagic anemia. 17. Patients with severe decreased cardiac function. 18. Patients with decreased platelet less than 75,000/μL..